![](/local/images//main/vitacoin/coin.png)
And it depends on you how soon it will be developed
![](/upload/iblock/c38/xc38120edd038dfe8be39b0218e087c67.png.pagespeed.ic.IKaFzokO_-.png)
The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
![](/upload/iblock/9d5/x9d57cd468fcf50473c172544afd0993e.jpg.pagespeed.ic.Mw7EwDvv4o.jpg)
Samsung Biologics (KRX: 207940.KS) announced that it has reached an agreement with Biogen for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion. The transaction is expected to boost earnings growth of Samsung Biologics on a consolidated basis, fully capitalizing on Samsung Bioepis’ growth outlook.
![](/upload/iblock/863/8636dbf4e8b88ea842f5e13fce978788.jpg)
A new technology that uses bio-printed ‘patches’ to repair damaged heart tissue has been proven to be safer and more cost-effective for patients.
![](/upload/iblock/bc4/bc4b8f1e499abc395fa9d28959f2e3d3.jpg)
The U.S. Food and Drug Administration has approved a new indication for Cytalux (pafolacianine) to assist surgeons in identifying lung cancer lesions in adult patients with known or suspected lung cancer.